November 9, 2006, the Presidents of BT Pharma and Cytheris, respectively Ben TImmerman and Michel Morre, presented their experience at two start-ups. The dinner debate was preceded by the elections of PharMBA's new bureau.
Michel Morre, Chairman and founding CEO of Cytheris, with a 30 years past in pharmaceutical research and industry, ex-MIT post-Doc, has an international experience of Drug research and management of large projects; in particular he managed at Sanofi-Aventis the full pre-clinical and clinical development of recombinant human growth hormone in Europe, which was the first biotech product introduced on the French market.
Dr Timmerman holds a PhD in Molecular Genetics from the University of Ghent, Belgium and an MBA from Insead, Fontainebleau, France. Ben has 16 years of management experience in senior positions in Life Science Companies such as Procordia, Sandoz and Novartis. Prior to founding BT PHARMA, Dr Timmerman founded a Biotech centre in Rio de Janeiro, Brazil, was Vice-President Research & Development of Novartis Seeds – Europe, member of the European Executive Committee and member of the global Technology Licensing and Acquisition team. Ben was also Board member of Agritrading, Italy.